The EU Malaria Fund is a public-private partnership between the European Union, International Organizations, corporations, and organized civic society, providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally.

Seven Facts about Plasmodium vivax

As of March 2019, Agustin Arasanz Duque has been named the new interim CEO of ITSL. Dr. Arasanz Duque is a senior consultant manager, with BS in Biology and Business Administration and Management from the University of Barcelona. Co-Founder of Hygeia Technologies S.L.  and over 10 years of experience in preparing business plans, IP and regulatory affairs, and scouting new biomedical companies with early stage technologies.

ITSL participates of a RIS3CAT Project: Noves estratègies per al control del virus de la síndrome respiratori i reproductiu porcí, RIS3CAT – COTPA – Regeva – COMRDDi16-1-0035-01 (2017-2020) co-financed by the European Regional Development Fund (FEDER)

Lorenzo José Fraile y Maria Montoya have recently joined ITSL as a new shareholders

ITSL at the IPVS & ESPHM 2016 Conference

Recently, research conducted by the ITSL R&D team have culminated with the publication of a research article in the prestigious journal Veterinary Research (Montaner-Tarbes et al. – 2016)

CSO of ITSL Coordinates a National Network of Excellenc in Research and Innovation on Exosomes (REDiEX) funded by MINECO.

CSO named President of the Spaniard Research group on Research and Development on Extracellular Vesicles (GEIVEX)